Off-label use of efalizumab in dermatology

References

• Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis.67(Suppl. 3), III64–III65 (2008).
   PubMed Web of Science ®Google Scholar
• Schon MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J. Invest. Dermatol.121(5), 951–962 (2003).
   PubMed Web of Science ®Google Scholar
• Dubertret L, Sterry W, Bos JD et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a Phase III international randomized, placebo-controlled trial. Br. J. Dermatol.155(1), 170–181 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA290(23), 3073–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med.349(21), 2004–2013 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J. Am. Acad. Dermatol.52(3 Pt 1), 425–433 (2005).
   PubMed Web of Science ®Google Scholar
• Papp KA, Bressinck R, Fretzin S et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a Phase IIIb, randomized, controlled trial. Int. J. Dermatol.45(5), 605–614 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br. J. Dermatol.159(3), 513–526 (2008).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Gordon KB, Lebwohl MG et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol.3(6), 614–624 (2004).
   PubMedGoogle Scholar
• Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J. Am. Acad. Dermatol.54(4 Suppl. 1), S154–S163 (2006).
   PubMedGoogle Scholar
• Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br. J. Dermatol.158(5), 1107–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Papp KA, Camisa C, Stone SP et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II. J. Cutan. Med. Surg.9(6), 313–323 (2005).
   Google Scholar
• Higgings JPT, Altman DG. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of interventions Version 5.0.1. Higgings JPT, Green S (Eds). The Cochrane Collaboration, Oxford, UK (2008).
   Google Scholar
• Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is ‘quality of evidence’ and why is it important to clinicians? BMJ336(7651), 995–998 (2008).
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Walicke P, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl. Immunol.9(2–4), 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Becker AB, Boulet LP et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol.112(2), 331–338 (2003).
   PubMed Web of Science ®Google Scholar
• Goncalves DP, Laurindo I, Scheinberg MA. The appearance of pustular psoriasis during antitumor necrosis factor therapy. J. Clin. Rheumatol.12(5), 262 (2006).
   PubMedGoogle Scholar
• Harper EG, Simpson EL, Takiguchi RH et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J. Invest. Dermatol.128(5), 1173–1181 (2008).
   PubMed Web of Science ®Google Scholar
• Jacquemin MG, Machiels JJ, Lebrun PM, Saint-Remy JM. Successful treatment of atopic dermatitis with complexes of allergen and specific antibodies. Lancet335(8703), 1468–1469 (1990).
   Google Scholar
• Su C, Teitelman M. Anti-TNF therapy: is this our answer to pyoderma gangrenosum. Gastroenterology131, 1347–1349 (2006).
   Google Scholar
• Callen JP. Immunomodulatory treatment for dermatomyositis. Curr. Allergy AsthmaRep.8(4), 348–353 (2008).
   Google Scholar
• Chen SL, Yan J, Lui Y, Xu XL, Sun JF, Wu TX. Efalizumab for psoriasis: a systematic review. Chinese J. Evidence-Based Med.6, 267–272 (2006).
   Google Scholar
• Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J. Am. Acad. Dermatol.53(1 Suppl. 1), S3–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Grassi W, Montecucco C. [Approved indications and other possible utilizations of anti-TNF-α biologic drugs.]. Reumatismo57(4 Suppl. 1), 30–33 (2005).
   Google Scholar
• Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J. Am. Acad. Dermatol.56(1), E55–E79 (2007).
   PubMedGoogle Scholar
• Guhl G, Diaz-Ley B, Fernandez-Herrera J. [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab]. Actas Dermosifiliogr.99(1), 5–33 (2008).
   PubMedGoogle Scholar
• Heymann WR. Antipsoriatic biologic agents for the treatment of atopic dermatitis. J. Am. Acad. Dermatol.56(5), 854–855 (2007).
   Google Scholar
• Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: a (2006) update. Semin. Cutan. Med. Surg.25(4), 226–240 (2006).
   Google Scholar
• O’Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J. Oral Pathol. Med.37(10), 575–581 (2008).
   PubMed Web of Science ®Google Scholar
• Prens EP. Off-label use and side-effects of biologics. Nederland Tijdschr. Dermatol. Venereol.18, 118–119 (2008).
   Google Scholar
• Wenzel J, Bieber T, Uerlich M, Tuting T. [Systemic treatment of cutaneous lupus erythematosus]. J. Dtsch. Dermatol. Ges.1(9), 694–704 (2003).
   Google Scholar
• Wakkee M, Assen YJ, Thio HB, Neumann HA. Repigmentation of vitiligo during efalizumab. J. Am. Acad. Dermatol.59(2 Suppl. 1), S57–S58 (2008).
   Google Scholar
• Cohen DJ, Scherschun L. Case reports: practical experience with efalizumab in hand and foot psoriasis. J. Drugs Dermatol.6(12), 1224–1230 (2007).
   Google Scholar
• Colsman A, Carrascosa JM, Ferrandiz C, Simon JC. Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab. J. Eur. Acad. Dermatol. Venereol.22(9), 1131–1134 (2008).
   PubMed Web of Science ®Google Scholar
• Fretzin S, Crowley J, Jones L, Young M, Sobell J. Successful treatment of hand and foot psoriasis with efalizumab therapy. J. Drugs Dermatol.5(9), 838–846 (2006).
   Google Scholar
• Stinco G, Piccirillo F, Patrone P. Treatment of palmoplantar pustular psoriasis with efalizumab: a quick response with early recurrence. Eur. J. Dermatol.18(1), 91–92 (2008).
   Google Scholar
• Varma R, Cafardi JA, Cantrell W, Elmets C. Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study. Am. J. Clin. Dermatol.9(2), 105–109 (2008).
   Google Scholar
• Wozel G, Vitez L. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm. Venereol.88(2), 169–170 (2008).
   Google Scholar
• Gomez M, Ruelas ME, Welsh O, Arcaute HD, Ocampo-Candiani J. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J. Drugs Dermatol.6(3), 337–339 (2007).
   Google Scholar
• Klein A, Szeimies RM, Landthaler M, Karrer S. Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology215(1), 72–75 (2007).
   Google Scholar
• Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br. J. Dermatol.158(2), 370–374 (2008).
   PubMed Web of Science ®Google Scholar
• Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J. Am. Acad. Dermatol.57(6), 1090–1091 (2007).
   PubMed Web of Science ®Google Scholar
• Bos JD. Proliferating prevalence of concepts and controversies in atopic eczema. J. Cosmet. Dermatol.3(4), 243–244 (2004).
   Google Scholar
• Takiguchi R, Tofte S, Simpson B et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J. Am. Acad. Dermatol.56(2), 222–227 (2007).
   PubMed Web of Science ®Google Scholar
• Farshidi A, Sadeghi P. Successful treatment of severe refractory atopic dermatitis with efalizumab. J. Drugs Dermatol.5(10), 994–998 (2006).
   Google Scholar
• Hassan AS, Kaelin U, Braathen LR, Yawalkar N. Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J. Am. Acad. Dermatol.56(2), 217–221 (2007).
   PubMed Web of Science ®Google Scholar
• Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J. Am. Acad. Dermatol.55(3), 529–532 (2006).
   PubMed Web of Science ®Google Scholar
• Siegfried EC. Long-term follow-up of a child treated with efalizumab for atopic dermatitis. Arch. Dermatol.143(8), 1077–1078 (2007).
   Google Scholar
• Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch. Dermatol.142(5), 555–558 (2006).
   PubMed Web of Science ®Google Scholar
• Sugerman PB, Savage NW, Walsh LJ et al. The pathogenesis of oral lichen planus. Crit. Rev. Oral. Biol. Med.13(4), 350–365 (2002).
   PubMedGoogle Scholar
• De Vries HJ, van MJ, Teunissen MB et al. Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. Br. J. Dermatol.154(2), 361–364 (2006).
   Google Scholar
• Bohm M, Luger TA. Lichen planus responding to efalizumab. J. Am. Acad. Dermatol.56(Suppl. 5), S92–S93 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch. Dermatol.142(6), 680–682 (2006).
   PubMedGoogle Scholar
• Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J. Drugs Dermatol.6(3), 310–314 (2007).
   Google Scholar
• Kolde G, Meffert H, Rowe E. Successful treatment of alopecia areata with efalizumab. J. Eur. Acad. Dermatol. Venereol.22(12), 1519–1520 (2008).
   Google Scholar
• Price VH, Hordinsky MK, Olsen EA et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J. Am. Acad. Dermatol.58(3), 395–402 (2008).
   PubMed Web of Science ®Google Scholar
• Tosti A, Pazzaglia M, Starace M, Bellavista S, Vincenzi C, Tonelli G. Alopecia areata during treatment with biologic agents. Arch. Dermatol.142(12), 1653–1654 (2006).
   PubMedGoogle Scholar
• Zribi H, Crickx B, Descamps V. Prevention of recurrent aphthous stomatitis by efalizumab (Raptiva). J. Eur. Acad. Dermatol. Venereol.21(9), 1286–1287 (2007).
   Google Scholar
• Goffe BS. Disseminated granuloma annulare resolved with the T-cell modulator efalizumab. Arch. Dermatol.140(10), 1287–1288 (2004).
   PubMed Web of Science ®Google Scholar
• Huber A, Gaffal E, Bieber T, Tuting T, Wenzel J. Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm. Venereol.86(3), 254–255 (2006).
   PubMed Web of Science ®Google Scholar
• Chow S, Rizzo C, Ravitskiy L, Sinha AA. The role of T cells in cutaneous autoimmune disease. Autoimmunity38(4), 303–317 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez-Obregon AC. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo. J. Drugs Dermatol.7(7), 679–681 (2008).
   Google Scholar
• WakkeeM, Thio HB, Neumann FJ. Is efalizumab effective in the treatment of vitiligo? Nederland Tijdschr. Dermatol. Venereol.18, 131–132 (2008).
   Google Scholar
• Wenzel J, Uerlich M, Worrenkamper E, Freutel S, Bieber T, Tuting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br. J. Dermatol.153(5), 1011–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, Tuting T. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br. J. Dermatol.157(4), 752–757 (2007).
   PubMed Web of Science ®Google Scholar
• Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J. Am. Acad. Dermatol.54(5), 892–895 (2006).
   PubMed Web of Science ®Google Scholar
• Hamprecht A, Tuting T, Bieber T, Wenzel J. Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clin. Exp. Dermatol.33(3), 347–348 (2008).
   Google Scholar
• Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch. Dermatol.143(7), 873–877 (2007).
   Google Scholar
• Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J. Am. Acad. Dermatol.54(5 Suppl.), S242–S243 (2006).
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Naldi L, Stern RS, Spuls PI. National Registries of Systemic Treatment for Psoriasis and the European ‘Psonet’ Initiative. Dermatology218(4), 347–356 (2008).
   Google Scholar
• Nijsten T, Spuls PI, Naldi L, Stern RS. The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab’s withdrawal. Arch. Dermatol.145(9), 1037–1039 (2009).
   PubMedGoogle Scholar